Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

PHASE3TerminatedINTERVENTIONAL
Enrollment

2,666

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Obesity
Interventions
DRUG

Rimonabant

Once daily in the morning

DRUG

Placebo

Once daily in the morning

Trial Locations (27)

Unknown

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Sofia

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Cairo

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Kallithea

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Dublin

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Vilnius

Sanofi-Aventis Administrative Office, Luxembourg

Sanofi-Aventis Administrative Office, Col. Coyoacan

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, Bratislava

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Geneva

Sanofi-Aventis Administrative Office, Istanbul

Sanofi-Aventis Administrative Office, Guildford Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00405808 - Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose | Biotech Hunter | Biotech Hunter